Table 1.
Patients characteristics.
| UPN | Diagnosis | Conditioning regimen | GvHD prophylaxis | GvHD | IS treatment at viral reactivation |
|---|---|---|---|---|---|
| 1 | ALL | TBI + VP16 | CSA + MTX + ATG | Acute skin grade II | CSA |
| 4 | ALL | TBI + VP16 | CSA + MTX + ATG | Acute skin + liver grade III | mPDN, MMF |
| 7 | MDS | BU + CY + MEL | CSA + MTX + ATG | Acute gut grade III | mPDN, MMF |
| 9 | MNGIE | BU + FLU | CSA + MTX + ATG | Acute gut grade III | mPDN |
| 10 | ALL | TBI + VP16 | CSA + MTX + ATG | Acute skin grade II | mPDN, CSA |
| 11 | AML | BU + CY + MEL | CSA + MTX + ATG | Acute skin + gut + liver grade IV | mPDN, MMF, ETANERCEPT |
| 13 | ALL | TREO + FLU | CSA + MTX + ATG | Acute skin grade II | CSA |
| 14 | ALL | TT + BU + FLU | CSA + MMF + EDX | Acute gut + liver grade III | mPDN, CSA |
| 15 | AML | TREO + FLU | CSA + MTX | Acute Skin + gut + liver grade III | mPDN, CSA |
| 16 | ALL | TBI + CY | CSA + mPDN + ATG | Acute gut + liver grade IV | CSA, mPDN, ECP, PENTOSTATIN IMATINIB, CAMPATH |
| 17 | AML | BU + CY | CSA + mPDN | Acute gut grade IV | mPDN, CSA |
IS: immunosuppression, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, MNGIE: mitocondrial neurogastrointestinal encephalomyopathy, TBI: total body irradiation, BU: busulfan, CY: cyclophosphamyde, MEL: melphalan, TREO: treosulfan, FLU: fludarabine, TT: Thiotepa, CSA: cyclosporine A, MTX: methotrexate, ATG: antithymocyte globulin, mPDN: methylprednisolon, MMF: mofetilmycophenolate, ECP: extracorporeal photopheresis. GvHD is graded according to NIH criteria.